"CofixRX is an antiviral nasal spray that offers up to 8 hours of protection from many cold and flu viruses." [from your CofixRx Nasal Spray product label] "Lasts for up to 8 hours per. The shown effects of azelastine nasal spray may thus be suggestive of azelastines potential as an antiviral treatment. Now, researchers at Swansea University will test it against Covid-19 Now, researchers at Swansea University. J. Infect. Generally, treatment with azelastine appeared safe in SARS-CoV-2 positive patients: no serious adverse events were reported in the current study, and the number of adverse events was comparable between groups. reviewed, edited and finalised the manuscript. COVID-19 nasal sprays may one day prevent and treat infection - ABC For hygiene reasons, it is preferable not to share the same nasal spray with other people. H.S. Dis. In a subset of patients (initial Ct<25) viral load was strongly reduced on day 4 in the 0.1% group compared to placebo (p=0.005). Importantly, newly emerging virus variants have the potential to evade the immune response, thereby affecting the efficacy of specific therapies and underlining the importance of new treatment strategies. Nineteen of those were common COVID-19 symptoms (shortness of breath [n=4], loss of smell [n=4], loss of taste [n=3], [muscle] weakness [n=2], tiredness/exhaustion [n=2], muscle ache, concentration impaired, headache, and cough). This observational study (HUN-VE: Hungarian Vaccine Effectiveness) estimated vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related mortality in 3.7 million . PubMed By blocking that access, compounds that target TMPRSS2 have the potential to be effective against both current and future variants. Carrageenan Nasal Spray for COVID-19 Prophylaxis (ICE-COVID) Sci. Information on individual variants was obtained through the original laboratory reports, when available. For quantification of SARS-CoV-2-RNA in copies/mL, a standard curve derived from a dilution series of a SARS-CoV-2 cell culture isolate in VTM and adjusted to Ct values obtained from two samples with defined SARS-CoV-2-RNA copy numbers (106 and 105 copies/mL; INSTAND e.V., Duesseldorf, Germany) was used. Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital, University of Cologne, Kerpener Str. Lee, K. (2022, April 27). N.W. You are using a browser version with limited support for CSS. For clarity reason, only cp/mL values of the ORF 1a/b gene are shown in the main text of the manuscript. Short intervals of swab collection time points, particularly during early days of infection, and high number of PCR tests aimed to monitor SARS-CoV-2 viral loads as closely as possible, considering that only limited knowledge regarding details of viral clearance was publicly available at the time of the study development. Small differences were found with regard to age and bmi, which were both slightly higher in the azelastine 0.1% group (supplementary Table S1). ADS How nasal-spray vaccines could change the pandemic, How much virus does a person with COVID exhale? contributed to the study conceptualisation. https://doi.org/10.1089/088318703322751327 (2004). Of note, 30 (non-related) adverse events in 13 patients (7 patients with 16 events in the 0.1% azelastine, 2 patients with 4 events in the 0.02% azelastine, and 4 patients with 10 events in the placebo group) were still ongoing at the final safety follow up on day 60. A., Dion, S. P., Buchholz, D. W., Imbiakha, B., Olmstead, A. D., Jager, M., Dsilets, A., Gao, G., Martins, M., Vandal, T., Thompson, C. A. H., Chin, A., Rees, W. D., Steiner, T., Nabi, I. R., Marsault, E., Sahler, J., Diel, D. G., . Nasal defence sprays Products such as Vicks First Defence nasal spray claim to trap and neutralise viruses in the nose before they have a chance to develop and spread. Med. Whether the current data can be extrapolated to other SARS-CoV-2 variants needs to be investigated. Cornell research team to develop COVID-19 nose spray treatment. Anna R. Mkel, PhD, senior scientist, Department of Virology, University of Helsinki, Finland. Google Scholar. This same site is shared among many variants of the COVID virus, so it could be effective against future variants as well, researchers note. URSAPHARM Arzneimittel GmbH, Saarbruecken, Germany is the sponsor of the clinical trial. Expert Opin. Jain, R. & Mujwar, S. Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19. Of those, 81 patients belonged to the Intention-To-Treat (ITT) population, comprising randomised patients meeting the key eligibility criteria and having evaluable viral load data on day 1 (baseline) and on day 11 (end of treatment). Comparably, differences in reduction of log10 viral load (cp/mL) in our study were0.63 (ORF 1a/b gene) comparing treatment with 0.1% azelastine to placebo. Therefore, during the treatment phase, patients were required to document the severity of their COVID-19 related symptoms in an electronic diary on a daily basis. Prevention is the best medicine, and COVID-19 vaccines block most SARS-CoV-2 infections. As expected, a continuous decrease in the mean virus load was observed in all study groups during the 11 treatment days. Of note, the mean viral load value showed small variability, thereby supporting the power of the current study. Monoclonal antibodies can block SARS-CoV-2 from . Treatment kits were manufactured by URSAPHARM Arzneimittel GmbH, Saarbruecken, Germany, according to the randomization list (as sequentially numbered containers). Get the most important science stories of the day, free in your inbox. In a highly relevant and translational in vitro model using reconstituted human nasal tissue, a fivefold diluted commercially available azelastine nasal spray solution inhibited viral replication almost completely within 72h after SARS-CoV-2 infection10. The median/mean viral load value (ORF 1a/b gene) of the ITT analysis set at enrolment was log10 7.23/6.851.31 cp/mL (approximately 7 million viral copies per mL, the highest values being~540 million cp/mL). Med. It can be used to help return your sense of smell if it was lost during a viral infection or minor head trauma. Jean, F. (2022). Researchers began to work on compounds that stifle TMPRSS2s ability to interact with the viral protein. However, examples of prolonged nasal positivity have also been reported, and many factors are known to have an influence on the individual viral load and clearance27. Intern. Trials underway to see if Boots cold remedy can tackle coronavirus Other evidence of viral infection showed similar differences between treated and untreated mice in the protective lining of cells called theepithelium inside the nose, nasal mucosa, and airways.. PDF Effect of nasal carriage of Bacillus species on COVID-19 severity: A Since the start of the Coronavirus Disease 2019 (COVID-19) pandemic, several independent research groups revealed azelastines potential as a promising candidate for drug repurposing to reduce SARS-CoV-2 viral load and infection rates5,6,7,8,9,10. March 31, 2023 An antiviral therapy in early development has the potential to prevent COVID-19 infections when given as a nasal spray as little as 4 hours before exposure. Provided by the Springer Nature SharedIt content-sharing initiative. Wiesmller (health authorities Cologne, Germany) for his support regarding regulatory issues, PD Dr. E. Raskopf for editorial assistance, and H. Papp for her assistance in PCR control experiments. Recent publications indicating that in vitro infectivity correlates with high virus concentrations (Ct25) in nasal swabs28,29,30 underline the importance of analysis of this subset population. At the end of the treatment, 48.2% of the patients of the 0.1% azelastine group showed no detection of the ORF 1a/b gene, whereas only 23.1% of patients of the placebo group showed negative PCR results (supplementary Table S4). The improvement of the symptom shortness of breath was significantly greater on days 3 (p=0.004) and 4 (p=0.011) in the 0.1% azelastine group compared to placebo (supplementary Figure S3). Currently, the jury is out on their effectiveness and evidence is still limited, but it's possible they could act as a prophylactic for a short period of time. Article A Boots nasal spray for cold and flu has shown positive results during testing to see if it could help tackle coronavirus infections. Pujadas, E. et al. Duration of culturable SARS-CoV-2 in hospitalized patients with covid-19. Nasal COVID Treatment Shows Early Promise Against Multiple Variants - WebMD Mitze, T. & Rode, J. Early-stage spatial disease surveillance of novel SARS-CoV-2 variants of concern in Germany with crowdsourced data. When treated with N-0385, 70% of the mice survived and had little to no lung damage. 11, 25262533. Because N-0385 was suitable for use as a nasal spray, researchers used a mouse model that develops severe COVID-19 and gave the mice either N-0385 or control doses of saline in their noses. Study finds nasal spray could aid battle against COVID Sign up for the Nature Briefing newsletter what matters in science, free to your inbox daily. Subgroups were analysed exploratorily (e.g., subgroups regarding gender, age, symptom severity, etc.). Researchers are developing coronavirus vaccines that will be sprayed up the nose. PubMed The Ct<25 group consisted of 19 patients in the 0.1% azelastine group, 21 patients in the 0.02% azelastine group and of 17 patients in the placebo group (Fig. Infect. New research has answers, COVID's future: mini-waves rather than seasonal surges, Are repeat COVID infections dangerous? . SARS-CoV-2 RNA levels in nasopharyngeal swabs were determined by quantitative RT-PCR using the cobas SARS-CoV-2 Test on the cobas 6800 system (Roche Diagnostic, Mannheim, Germany). Patient disposition. The overall AUC of the Azelastine 0.1% group (red area) was significantly greater than that of placebo (green area), p=0.007. The researchers compared mice treated with TriSb92 before and after exposure to SARS-CoV-2. Boots Dual Defence Nasal Spray is used to dampen the symptoms of cold and flu. Reznikov et al. It should be noted that the SARS-CoV-2 alpha variant (B.1.1.7) was the dominant variant in Germany during the enrolment phase of the current study16. Secondary endpoints included the assessment of symptoms, patient status (using a 11-category ordinal score as proposed by the WHO11), body temperature and blood oxygen saturation, quality of life (reported in the SF-36 generic quality of life questionnaires) and safety (adverse events, including worsening of patient status/symptoms) over time. Article ICE-COVID a randomised, double blind, placebo-controlled phase III trial of the prophylactic efficacy of iota-carrageenan nasal and throat spray in preventing COVID-19 illness in at risk healthcare professionals. Get the most important science stories of the day, free in your inbox. Now, researchers at Swansea University will test Boots' Dual Defence Nasal Spray, which costs 5.99 for 20ml, against Covid-19. Google Scholar. A study of frontline workers is looking into how a Boots nasal spray could prevent Covid-19. All rights reserved. Suitable for A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Wlfel, R. et al. Ku Z, Xie X, Hinton PR, Liu X, Ye X, Muruato AE, Ng DC, Biswas S, Zou J, Liu Y, Pandya D, Menachery VD, Rahman S, Cao . Comirnaty may help your body develop immunity to SARS-CoV-2, the virus that causes COVID-19. FH is the CEO of URSAPHARM Arzneimittel GmbH. Can Nasal Sprays Treat or Prevent COVID-19? - GoodRx Lett. Article Of note, pharmacometric analyses of our data indicate that more frequent applications of the nasal spray may be more appropriate for efficient treatment35. The team will enrol 480 healthworkers, including nurses and doctors . One puff of the respective nasal spray was applied per nostril, 3 times a day (morning, midday, evening). By submitting a comment you agree to abide by our Terms and Community Guidelines. Zapor, M. Persistent detection and infectious potential of SARS-CoV-2 virus in clinical specimens from COVID-19 patients. J. During the throes of the COVID-19 pandemic, Anne Moscona didnt feel safe going to a restaurant or catching a flight. Researchers at Swansea University will begin human trials this week following a successful study suggests the 5.99 remedy, Dual Defence, could help reduce infections thanks to its special ingredient - seaweed . drafted the manuscript. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Article JPK and CL have received grants from the sponsor URSAPHARM Arzneimittel GmbH for performing this trial. Public Health 3, 21. https://doi.org/10.1007/BF02959944 (1995). Promising nose spray could prevent and treat COVID-19 Study endpoints were presented by descriptive statistics, aiming to compare the course of viral load between the three treatment groups. The company led byMkel is now working to secure funding for clinical trials of TriSb92 in humans.. Ther. Virological assessment of hospitalized patients with COVID-2019. The trial protocol and the data are however available from the authors upon reasonable request and with permission of URSAPHARM Arzneimittel GmbH. It was assumed that all treatment groups present identical baseline virus load at enrolment with a mean value of 5.5 log10 copies/mL3 SD13,14. All tests were performed two-sided and the type 1 error () was set to 5%. Hamasaki, Y. et al. Sci Rep 13, 6839 (2023). What the science says, Racial inequalities deepened in US prisons during COVID, The WHO at 75: what doesnt kill you makes you stronger, White House to tap cancer leader Monica Bertagnolli as new NIH director, Massive mosquito factory in Brazil aims to halt dengue, Seeks to identify an outstanding Scientific Director to lead its Division of Preclinical Innovation (DPI) in Rockville, Maryland. This is similar to the natural SARS-CoV-2 clearance time of approximately 2weeks. The study was termed CARVIN (referring to COVID-19: Azelastine nasal spray Reduces Virus-load In Nasal swabs). Both have the allure of being variant-proof, Topol added., Many laboratories are shifting from treatments using monoclonal antibodies to treatments using smaller antibody fragments called "nanobodies" because they are more cost-effective and are able to last longer in storage, Mkel and colleagues noted., Several of these nanobodies have shown promise against viruses in cell culture or animal models, including as an intranasal preventive treatment for SARS-CoV-2.. If delivery took place within 24h after sampling, samples were to be stored at<25C, if storage period was greater than 24h (e.g., on Sundays), samples had to be stored and shipped at 28C. 62, 50937, Cologne, Germany, Jens Peter Klussmann,Maria Grosheva,Paula Aguiar de Arago,Henning Morr&Helal Al Saleh, URSAPHARM Arzneimittel GmbH, Industriestrae 35, 66129, Saarbruecken, Germany, Peter Meiser,Michael Flegel,Frank Holzer,Dorothea Gro,Charlotte Steinmetz&Barbara Scherer, Department I of Internal Medicine, Division of Infectious Diseases, University of Cologne, Kerpener Str. Recently, Shmuel et al. The data that support the findings of this study are available from URSAPHARM Arzneimittel GmbH but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. 31(6), 113. Samples of day 1 represent pre-treatment baseline samples. 147, 400401. When the treatment course was shortened to four days, starting one day before infection, all 10 of the mice treated with N-0385 survived. Overall, the current results are encouraging; however, further studies should be carried out to strengthen the findings, and treatment should be extended to other age and risk groups and cover individuals with different levels of symptom severity.